Daftar ini adalah analisis berdasarkan peristiwa pasar terbaru. Ini bukan rekomendasi investasi.
Tentang
Shanghai Microport Medbot (Group) Co., Ltd. engages in the research and development, design, manufacture, and sale of surgical robots in the People's Republic of China and Europe. It offers Toumai, a laparoscopic surgical robot for use in urologic, gynecologic, thoracic, and general surgeries; DFVision, a 3D electronic laparoscope, which is used in laparoscopic surgeries for abdominal, thoracic, and pelvic organs; Honghu, an orthopedic surgical robot for knee arthroplasty and hip arthroplasty; R-One, a vascular interventional surgical robot for coronary angioplasty; and iSR'obot, a Mona Lisa robotic transperineal prostate biopsy system. The company also provides spine surgical robots; trans-bronchial surgical robots for trans-bronchial diagnosis and treatment; TAVR surgical robots for heart valve replacement surgery; and automated needle targeting robotics systems for percutaneous lung biopsy and percutaneous nephrolithotomy. Shanghai Microport Medbot (Group) Co., Ltd. was founded in 2014 and is based in Shanghai, China. Shanghai Microport Medbot (Group) Co., Ltd. operates as a subsidiary of MicroPort Scientific Corporation.
Apa simbol saham Shanghai MicroPort MedBot (Group)Ltd.?▼
Tergantung pada bursa, simbol saham dapat berbeda. Misalnya, di bursa , saham Shanghai MicroPort MedBot (Group)Ltd. diperdagangkan dengan simbol SGMMY.
Kapan tanggal laporan keuangan berikutnya dari Shanghai MicroPort MedBot (Group)Ltd.?▼
Shanghai MicroPort MedBot (Group)Ltd. akan merilis laporan keuangan berikutnya pada September 02, 2026.
Berapa jumlah karyawan Shanghai MicroPort MedBot (Group)Ltd.?▼
Per April 08, 2026, perusahaan memiliki 1,200 karyawan.
Shanghai MicroPort MedBot (Group)Ltd. berada di sektor apa?▼
Shanghai MicroPort MedBot (Group)Ltd. beroperasi di sektor Healthcare.